Data for Metabolomics of bariatric weight loss (Study ST000743)

(Analysis AN001161)

Values for each metabolite have been scaled by dividing by the mean across all factors

Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

MetaboliteF1F2F3F4F5F6F7F8
CerP 32:1; [M-H]-@5.13 1.0696 1.0740 1.0455 0.9289 0.4865 0.8947 0.7334 1.3366
CerP 34:1; [M-H]-@5.84 0.9867 1.0580 1.4758 0.9159 0.8450 0.5397 1.0547 0.9902
CerP 34:2; [M-H]-@5.34 1.2584 1.0053 1.1622 0.7070 0.4697 0.9933 0.7316 0.8816
CL 72:5; [M-2H](2-)@6.24 0.8524 1.2171 0.6718 1.2389 0.9389 0.8401 1.3527 0.6795
CL 74:5; [M-2H](2-)@6.55 1.1103 0.9648 0.7094 1.3033 0.7099 1.3073 1.2730 0.3969
CL 74:7; [M-2H](2-)@6.09 0.9898 1.2342 1.4301 0.9275 0.5770 0.9376 0.9292 0.3023
CL 78:5; [M-2H](2-)@6.45 1.1001 0.9304 1.0381 0.8259 1.0745 0.5769 1.0505 1.3121
CL 82:15; [M-2H](2-)@5.91 0.8099 1.5250 1.0516 0.8417 0.5858 0.5989 1.1427 0.4394
FFA(16:0) 1.0794 1.1010 1.2318 0.7296 0.6901 0.9275 0.6875 1.0121
FFA(18:0) 1.0877 1.0642 1.0128 0.7530 0.7552 1.0528 0.7530 1.0654
FFA(18:1) 0.9993 1.0859 1.8046 0.9192 0.8712 0.3948 0.8007 0.8686
FFA(18:2) 0.9899 1.0706 1.9065 0.7711 0.7410 0.6227 0.8572 0.8591
FFA(20:0) 1.0900 1.0133 0.9424 0.8316 0.7364 1.1889 0.7791 1.1084
FFA(20:1) 0.8834 1.1506 2.2600 0.9084 0.8950 0.3367 0.7235 0.7404
FFA(20:2) 1.0515 1.2260 1.8258 0.6894 0.5824 0.5835 0.4772 0.7318
FFA(20:4) Arachidonic acid 0.8460 1.4694 2.0003 0.4345 0.4161 0.6485 0.4761 0.7627
FFA(22:0) 0.9585 0.9731 1.0764 1.0005 0.9703 0.7827 1.3807 1.0628
FFA(22:1) 0.9809 1.1199 1.3268 0.9659 0.7326 0.7103 0.9147 0.9466
FFA(22:2) 0.8890 1.3860 1.6013 0.8529 0.6550 0.4271 0.6054 0.7581
FFA(22:3) 0.7404 1.4529 1.7469 1.0555 0.6255 0.3943 0.8072 0.5973
FFA(24:0) 0.9212 1.0047 1.4945 0.6439 0.6540 1.3812 1.0910 1.0316
FFA(24:1) 0.8131 1.1873 2.0449 0.7622 0.6584 0.6003 1.1151 0.8174
FFA(24:2) 0.7929 1.1644 2.3175 1.0585 0.6635 0.4475 1.0189 0.6649
FFA(24:3) 0.8584 1.2464 1.7441 0.8923 0.7317 0.6555 1.2871 0.2701
lysoPE 16:0; [M-H]-@1.65 1.0219 1.2611 1.1360 1.2917 0.5350 0.3998 0.7817 0.7237
lysoPE 17:0; [M-H]-@2.05 0.7895 1.4321 1.3640 0.4178 0.8017 0.9762 0.5437 1.0099
lysoPE 18:0; [M-H]-@2.44 1.2298 1.2044 1.0192 0.8770 0.4975 0.4817 0.5423 0.8456
lysoPE 18:1; [M-H]-@1.83 1.0735 1.1549 0.6839 0.9618 0.4544 0.8646 1.0966 1.0250
lysoPE 18:2; [M-H]-@1.37 1.2319 0.7924 0.7603 1.3176 0.5271 1.2897 1.0071 1.0010
lysoPE 20:3; [M-H]-@1.63 1.0650 1.1397 0.7067 1.8212 0.6377 0.3108 0.9181 0.7869
lysoPE 20:4; [M-H]-@1.34 1.0266 1.1944 1.4194 0.8113 0.4926 0.5825 0.9527 0.8573
lysoPE 22:5; [M-H]-@1.54 1.0045 1.3434 1.1448 1.0750 0.4574 0.3987 0.8135 0.7189
lysoPE 22:6; [M-H]-@1.30 1.0481 1.2743 1.5527 0.4813 0.6613 0.4656 0.7485 0.8012
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.47 0.7917 1.2087 2.1750 0.9911 0.8696 0.5911 0.9762 0.3953
N-(docosanoyl)-sphing-4-enine; [M-H]-@8.46 0.9152 1.0899 1.5763 0.7936 0.7589 0.5364 1.3757 0.9389
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.84 0.8408 0.8928 2.5093 1.1398 0.7283 0.3677 1.1074 1.2135
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.44 0.9152 1.2283 2.7377 0.7224 0.4247 0.4050 0.5867 0.5495
N-(octadecanoyl)-sphinganine; [M-H]-@7.61 0.9664 0.8688 4.0115 0.8942 0.1435 0.1090 1.1779 0.3232
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.92 0.8293 1.1494 1.3938 1.1382 0.8747 0.8524 0.9160 0.9099
PA 34:1; [M-H]-@6.72 0.8937 1.1086 1.3647 0.9999 1.0990 0.8994 0.8662 0.7616
PA 34:2; [M-H]-@6.28 0.9899 0.8627 0.9427 1.2227 1.5443 0.7983 0.9245 1.1570
PA 36:4; [M-H]-@6.24 1.0788 1.0755 0.5705 1.1538 0.6949 0.9619 0.5315 1.4699
PC 28:0; [M-Ac-H]-@5.28 0.7874 1.1772 0.9266 2.2891 0.9963 0.3522 0.6748 0.9029
PC 30:2; [M-Ac-H]-@4.92 0.5470 1.0939 0.2896 2.2695 1.1313 0.7176 0.6235 2.4050
PC 32:2; [M-Ac-H]-@5.61 1.1337 0.9314 0.4071 1.9249 0.8040 0.3567 1.2394 1.0076
PC 32:3; [M-Ac-H]-@5.18 1.0183 0.9842 0.4944 1.2650 0.5010 1.1492 0.9218 1.6588
PC 33:1; [M-Ac-H]-@6.46 1.2554 1.1378 0.9560 0.8635 0.6720 0.6052 0.5807 0.7498
PC 33:2; [M-Ac-H]-@6.00 1.0252 0.8343 1.1911 1.2476 1.0197 0.8462 1.2134 1.0439
PC 34:3; [M-Ac-H]-@5.81 1.2872 1.0945 0.6567 0.5672 0.5594 0.8829 0.7730 1.0340
PC 34:4; [M-Ac-H]-@5.54 0.9953 1.2873 0.7332 1.2191 0.3702 0.4550 1.0604 1.0316
PC 35:1; [M-Ac-H]-@7.09 0.9238 1.2197 1.0237 0.8809 0.8368 0.6756 0.7610 1.2483
PC 35:2; [M-Ac-H]-@6.58 1.0140 0.8751 1.1193 1.0655 1.0573 0.7666 1.1365 1.2985
PC 35:3; [M-Ac-H]-@6.12 0.9247 0.9920 1.7370 0.7005 0.3672 0.9458 1.8605 0.7223
PC 35:4; [M-Ac-H]-@5.94 0.8597 1.0034 1.3359 1.4059 0.4424 0.4995 1.7835 1.0805
PC 36:5; [M-Ac-H]-@5.70 0.9869 1.2526 0.8106 0.8730 0.5848 0.5050 1.2260 1.0426
PC 37:2; [M-Ac-H]-@7.24 0.8812 0.8581 0.3124 1.2701 0.9816 1.3041 0.7848 2.3898
PC 37:3; [M-Ac-H]-@6.77 1.1086 0.9666 1.0262 1.0869 1.1836 0.5286 0.5762 1.2979
PC 37:4; [M-Ac-H]-@6.53 0.9797 1.0880 1.6356 1.1663 0.6155 0.6365 0.9141 0.7615
PC 37:5; [M-Ac-H]-@6.06 0.8372 1.1634 1.5726 0.8963 0.7084 0.6059 1.0919 1.1224
PC 37:6; [M-Ac-H]-@5.80 0.9662 1.0723 1.7747 0.7211 1.0013 0.3998 0.9493 0.9998
PC 38:2; [M-Ac-H]-@7.51 1.0943 0.9827 0.6752 1.2586 0.5997 1.2852 0.6694 1.2038
PC 39:5; [M-Ac-H]-@6.66 0.9620 1.0717 1.7745 0.6579 0.9532 0.9075 0.5303 1.0417
PC 39:6; [M-Ac-H]-@6.46 1.0942 1.0957 1.4169 0.4912 1.5597 0.4620 0.7453 0.5650
PC 40:4; [M-Ac-H]-@7.33 0.9295 1.1542 0.9517 1.4209 0.7069 0.5681 1.2250 0.7927
PC 40:5; [M-Ac-H]-@7.06 0.9133 1.1539 1.4695 1.0318 0.7569 0.5018 0.9713 0.9997
PC 40:6; [M-Ac-H]-@6.69 1.1922 1.1262 1.0923 0.4456 0.7694 0.7193 0.6255 1.0742
PC 40:8; [M-Ac-H]-@5.80 0.8007 0.9631 0.9867 1.7475 1.4622 0.5539 1.2440 0.9503
PC 40:9; [M-Ac-H]-@5.38 0.8239 1.1896 1.4191 1.3717 0.8640 0.4170 1.7748 0.0991
PC 42:10; [M-Ac-H]-@5.75 0.9139 0.6868 0.5920 2.3597 1.3486 0.6657 0.8514 1.7797
PE 32:0; [M-H]-@6.75 1.0541 1.3262 1.1704 1.0421 0.4291 0.4342 0.8459 0.5572
PE 32:1; [M-H]-@6.24 1.0358 1.1758 0.5399 2.6710 0.7166 0.2615 0.6509 0.3135
PE 33:1; [M-H]-@6.53 1.0518 1.3894 0.3989 1.9547 0.4443 0.1810 0.9506 0.3053
PE 33:2; [M-H]-@6.06 1.1373 0.9571 1.1926 1.6234 0.5523 0.5556 0.8674 0.8311
PE 34:1; [M-H]-@6.86 1.0950 1.3943 0.8111 0.9198 0.4028 0.7075 0.8388 0.3627
PE 34:2; [M-H]-@6.42 1.1101 0.9468 1.0249 1.2680 0.6507 1.0939 1.2180 0.5169
PE 34:3; [M-H]-@5.95 1.1463 0.9313 0.9230 1.4090 0.4681 0.8133 1.6814 0.3948
PE 35:1; [M-H]-@7.12 1.2253 1.1636 0.7914 0.5650 0.8966 0.6947 1.1578 0.3392
PE 35:2; [M-H]-@6.68 1.0863 0.9281 0.9676 1.4126 0.6773 0.7660 1.5245 0.5943
PE 35:4; [M-H]-@6.06 1.0157 1.3444 1.5004 0.9153 0.3896 0.2403 1.2083 0.3055
PE 36:0; [M-H]-@7.86 1.1063 1.0664 1.0835 0.7633 0.8372 1.1903 0.6741 0.7610
PE 36:1; [M-H]-@7.44 0.9953 1.1002 0.5193 1.0206 0.6897 0.9395 1.7851 0.6639
PE 36:2; [M-H]-@6.99 1.0863 0.8488 0.7005 1.3350 0.8947 1.1412 1.5074 0.6810
PE 36:3; [M-H]-@6.54 1.0089 0.9601 0.7840 1.3749 0.5173 1.4824 1.4898 0.4757
PE 36:4; [M-H]-@6.22 0.9437 1.2722 1.5924 0.9225 0.4035 0.9111 0.9429 0.3639
PE 36:5; [M-H]-@5.96 0.9434 1.3264 0.8947 1.2767 0.4700 0.3850 1.4218 0.4724
PE 36:6; [M-H]-@5.61 0.6483 1.8082 0.6183 0.7020 0.6240 0.4520 1.0351 0.7423
PE 37:2; [M-H]-@6.45 0.9020 0.9105 0.4989 0.8469 1.0138 0.5803 1.3834 2.4265
PE 37:3; [M-H]-@6.92 0.7230 1.3959 1.0498 1.2003 0.5635 0.7204 1.2758 0.7150
PE 37:4; [M-H]-@6.65 1.0403 1.4355 1.3650 0.6390 0.4160 0.5311 0.6486 0.4970
PE 37:5; [M-H]-@6.19 1.0896 1.3254 0.7233 0.5740 0.8552 0.8858 0.6409 0.6609
PE 37:6; [M-H]-@5.97 1.0551 1.5071 1.2663 0.5865 0.5129 0.1454 1.1461 0.0939
PE 38:1; [M-H]-@7.35 0.6917 1.0655 0.9797 1.4660 0.7936 1.0468 1.2861 1.3989
PE 38:2; [M-H]-@6.86 1.0832 0.7422 1.2912 1.2519 0.8562 0.6583 1.3910 1.2496
PE 38:3; [M-H]-@6.49 0.9001 0.9271 1.3456 1.3224 1.0399 0.5453 1.1698 1.2682
PE 38:5; [M-H]-@6.51 0.8684 1.4355 1.3852 0.9198 0.4508 0.4568 1.2399 0.3317
PE 38:6; [M-H]-@6.12 0.9148 1.4127 1.8671 0.4382 0.7204 0.3037 1.0907 0.2697
PE 38:7; [M-H]-@5.81 0.8510 1.4091 1.8223 0.8588 0.3902 0.1809 1.2913 0.4164
PE 39:6; [M-H]-@6.56 0.9653 1.6567 1.0673 0.4060 0.6144 0.3210 0.7532 0.3499
PE 40:3; [M-H]-@7.12 1.2797 0.8845 1.0774 0.5708 1.0760 0.8822 0.8861 0.8509
PE 40:4; [M-H]-@7.42 1.2055 1.3134 0.7012 0.9159 0.3925 0.7615 0.8768 0.2768
PE 40:5; [M-H]-@7.12 0.8719 1.4981 1.0880 0.7973 0.6853 0.5395 0.9616 0.4482
PE 40:6; [M-H]-@6.89 1.0364 1.4255 1.0478 0.4821 0.6257 0.5221 1.0944 0.3803
PE 40:7; [M-H]-@6.38 0.8387 1.6452 1.0749 0.3608 0.5862 0.6253 1.1290 0.2884
PE 40:8; [M-H]-@5.99 0.8176 1.5615 1.3407 0.7543 0.4592 0.4504 1.0505 0.4283
PG 32:0; [M-H]-@5.80 0.9598 1.0248 0.2412 1.5896 0.6333 0.7103 0.8456 2.0418
PG 33:0; [M-H]-@6.09 1.0261 1.0671 0.3810 0.9264 0.5577 0.8879 1.2874 1.5869
PG 33:1; [M-H]-@6.55 1.0494 0.8657 1.3059 0.9487 0.9600 1.0268 0.6368 1.4614
PG 34:2; [M-H]-@5.50 0.8102 1.0785 1.1328 1.3021 0.6104 1.1008 1.6458 0.6532
PG 36:0; [M-H]-@6.90 1.1495 0.9520 1.1772 0.7234 0.6935 1.1825 0.7313 1.0858
PG 36:1; [M-H]-@6.44 1.1746 1.0595 0.4991 0.5455 0.9109 0.7165 1.6298 0.7615
PG 36:2; [M-H]-@5.97 0.9246 1.2650 0.9803 0.9594 0.6301 0.6653 1.6683 0.3379
PG 36:3; [M-H]-@5.33 0.8881 1.1260 0.6872 2.0760 0.7405 0.7150 1.3012 0.4238
PG 38:4; [M-H]-@6.09 1.1117 0.7747 1.1001 0.9979 0.7271 0.6453 2.2957 0.6885
PI 34:1; [M-H]-@5.74 0.9265 0.9981 0.8289 2.2878 1.2783 0.3090 0.9492 0.6486
PI 34:2; [M-H]-@5.28 1.1979 0.9067 0.6404 1.8768 0.8803 0.5305 0.8029 0.8507
PI 36:1; [M-H]-@6.34 0.6559 1.1523 0.4238 1.2175 1.7408 1.2507 1.2728 0.8613
PI 36:2; [M-H]-@5.95 1.0502 0.8141 1.0211 1.5924 1.1407 0.5220 1.6370 0.6294
PI 36:3; [M-H]-@5.41 0.8991 0.8449 0.9852 1.9024 1.0737 0.5681 1.4404 1.0541
PI 36:4; [M-H]-@5.28 0.8879 1.0235 0.8790 2.4815 0.7830 0.3875 0.9202 0.9031
PI 38:3; [M-H]-@6.13 0.7693 1.0128 1.1007 1.8146 1.5249 0.4850 1.0888 0.8579
PI 38:4; [M-H]-@5.88 0.8124 1.1737 1.4007 1.3482 1.1401 0.3582 1.2030 0.6053
PI 38:5; [M-H]-@5.35 0.8570 0.9506 0.4025 1.6981 0.8656 0.6517 0.9870 2.1646
PI 40:5; [M-H]-@5.99 0.8304 1.0010 1.2840 1.7216 1.7056 0.3507 1.0598 0.5523
PI 40:6; [M-H]-@5.84 0.9590 1.0712 1.3157 0.9373 1.5098 0.2561 1.2487 0.6119
plasmenyl-PE 32:1; [M-H]-@6.58 0.9530 1.1614 0.6457 1.3046 1.1095 0.5673 1.2416 0.6737
plasmenyl-PE 34:0; [M-H]-@7.23 0.8809 1.1508 1.4465 0.9793 0.9749 0.4787 1.0298 0.9638
plasmenyl-PE 34:1; [M-H]-@7.16 0.8534 1.3009 0.9635 0.7271 1.0325 0.8388 1.0607 0.7604
plasmenyl-PE 34:2; [M-H]-@6.71 0.8565 1.0143 0.7407 1.0003 1.4426 0.7593 1.4617 1.1121
plasmenyl-PE 34:3; [M-H]-@6.33 0.7652 0.8267 0.7010 0.9809 1.6319 0.8649 1.6276 1.8264
plasmenyl-PE 36:1; [M-H]-@7.73 0.8156 1.3091 0.7473 0.7720 0.9518 0.8877 1.2574 0.8852
plasmenyl-PE 36:2; [M-H]-@7.33 0.8808 1.0804 0.7789 0.7918 1.4465 0.8682 1.2411 1.0283
plasmenyl-PE 36:3; [M-H]-@6.90 0.8758 1.0521 1.0244 0.9235 1.2939 0.8838 1.2058 0.9569
plasmenyl-PE 36:4; [M-H]-@6.65 0.8776 1.2546 1.4697 0.6678 0.9569 0.7125 0.8057 0.8585
plasmenyl-PE 36:5; [M-H]-@6.28 0.6955 0.9537 0.7020 0.7292 2.6626 0.4985 1.2997 1.5115
plasmenyl-PE 38:1; [M-H]-@8.25 1.2547 1.1297 0.6947 0.3291 0.4685 1.1194 0.8889 0.9618
plasmenyl-PE 38:2; [M-H]-@7.83 0.8926 1.3133 0.9197 0.6430 0.8068 1.0802 1.0088 0.7179
plasmenyl-PE 38:3; [M-H]-@7.53 0.8121 1.1843 1.2834 0.8763 1.1641 0.6521 0.9894 1.0493
plasmenyl-PE 38:4; [M-H]-@7.24 0.8638 1.1909 1.2505 0.9512 1.2670 0.7453 0.8622 0.7052
plasmenyl-PE 38:5; [M-H]-@6.74 0.8678 1.0090 1.7903 0.9056 1.2606 0.5364 1.0472 0.9529
plasmenyl-PE 38:6; [M-H]-@6.52 0.8739 1.1247 1.8006 0.6603 1.0929 0.6473 0.9185 0.8858
plasmenyl-PE 40:3; [M-H]-@8.06 0.9877 1.0393 0.4996 0.9783 0.6396 1.2543 0.9115 1.6089
plasmenyl-PE 40:4; [M-H]-@7.76 0.9672 1.2159 1.4173 0.8260 0.6404 0.7843 0.9859 0.6140
plasmenyl-PE 40:5; [M-H]-@7.37 0.8704 1.0563 1.8912 1.0831 0.8126 0.7710 0.8214 0.9138
plasmenyl-PE 40:6; [M-H]-@7.17 0.9304 1.0519 1.8679 0.5699 1.1989 0.5412 0.8741 1.0188
plasmenyl-PE 42:5; [M-H]-@7.88 1.0865 1.1712 1.3008 0.6675 0.7254 0.5965 0.9104 0.7688
plasmenyl-PE 42:6; [M-H]-@7.75 1.2435 1.0817 1.1703 0.7202 0.8091 0.6283 0.9370 0.4343
PS 38:4; [M-H]-@6.00 1.4366 0.4204 0.9676 1.0122 1.1486 1.9808 0.7071 0.7560
Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study

Factors:

F1Gender:female | Glycemic status:diabetic | Neuropathy:Neuropathy
F2Gender:female | Glycemic status:diabetic | Neuropathy:no neuropathy
F3Gender:female | Glycemic status:normoglycemic | Neuropathy:Neuropathy
F4Gender:female | Glycemic status:normoglycemic | Neuropathy:no neuropathy
F5Gender:male | Glycemic status:diabetic | Neuropathy:Neuropathy
F6Gender:male | Glycemic status:diabetic | Neuropathy:no neuropathy
F7Gender:male | Glycemic status:pre-diabetic | Neuropathy:Neuropathy
F8Gender:male | Glycemic status:pre-diabetic | Neuropathy:no neuropathy
  logo